Regulatory November date set for FDA decision on Sanofi’s Gaucher drug PharmaphorumThe FDA has started a priority review of Sanofi's brain-acting Gaucher disease therapy venglustat, with an action date of 25th November.Rare DiseaseRead full story pharminent May 28, 2026 (Last updated: May 30, 2026) Pharmaphorum The FDA has started a priority review of Sanofi’s brain-acting Gaucher disease therapy venglustat, with an action date of 25th November. Rare Disease Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Kailera’s three-pronged obesity shot shows promise in early trialNext: AbbVie snags FDA’s first ADC approval for ultra-rare blood cancer Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
